

REMARKS**Specification**

The Office communication indicated that the title of the invention is not descriptive. Accordingly, a more descriptive title is provided.

In an earlier amendment, the cross reference to related applications was amended to remove the cross reference to two patent applications that have now issued into patents. By so doing, the incorporation by reference for these two applications was inadvertently removed. The amendment to the specification is intended to correct this error and to reinstate the incorporation by reference of these two applications.

Claim Rejections -- 35 USC §102

Claims 71, 72, 75, 76, 78-90 were rejected as being anticipated by DeFord et al. (US 5,304,214). Independent claims 71, 82, and 87 have been amended to claim a standalone implantable power module that can be used to power a variety of different medical electronic devices or a method of using a standalone implantable power module that can be used to power a variety of different medical electronic devices. In '214, the power supply 38 is included within the internal control unit 16, which includes RAM 94 that enables a patient to be able to undergo hyperthermia treatment while away from the external control unit 22. That is, the power supply 38 is located within the medical device itself, internal control unit 16. Clearly, '214 does not teach a standalone implantable power module that can be used to power a variety of different medical devices.

Claim Rejections -- 35 USC §103

Claims 73, 74, and 77 were rejected as being unpatentable over DeFord et al. (US 5,304,214). The Office communication stated:

Regarding claim 73, it would have been obvious to one having ordinary skill in the art at the time the invention was made to have provided the power source with at least one primary battery, since it has been held that omission of an element and its function in a combination where the remaining elements perform the same functions as before involves only routine skill in the art.

However, it is submitted that Applicant's invention does not *omit* an element; it *adds* a primary battery. Furthermore, these claims depend from claim 71, which should be patentable for the reasons that claim 71 is patentable.


Double Patenting

Claims 71-90 were provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 71-336 of copending Application No. 10/310,390. Applicant believes that the amended and newly added claims are patentable over claims 71-336 of copending Application No. 10/310,390. If it is determined that a terminal disclaimer is still necessary to overcome the rejection, the Examiner is respectfully requested to telephone the undersigned.

Conclusion

Favorable consideration of the claims is thought to be in order and is courteously solicited.

Respectfully submitted,



MARY ELIZABETH BUSH

Reg. No. 38,402

Agent for Applicant(s)

Quallion LLC
P.O. Box 923127
Sylmar, CA 91392-3127
818-833-2003 ph
818-833-2065 fax



Office Action Summary

Application No.

10/310,390

Applicant(s)

TSUKAMOTO ET AL.

Examiner

Edward H Tso

Art Unit

2838

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 19 November 2003.
- 2a) ☐ This action is FINAL. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-70 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-19, 31-33, 36-65, 67 and 68 is/are rejected.
- 7) ☒ Claim(s) 20-30, 34, 35, 66, 69 and 70 is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 19 November 2003 is/are: a) ☒ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. §§ 119 and 120

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
* See the attached detailed Office action for a list of the certified copies not received.
- 13) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.
a) ☐ The translation of the foreign language provisional application has been received.
- 14) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.

Attachment(s)

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). _____
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) _____ 6) ☐ Other: _____

DETAILED ACTION

Information Disclosure Statement

The IDS filed 11/19/2003 and its duplicate filed 11/24/2003 have been considered placed of record. An initialed copy is attached herewith.

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1, 5, 10, 17, 31-33, 67 and 68 are rejected under 35 U.S.C. 102(b) as being anticipated by MICHELSON (US 6,120,502). The reference discloses, *inter alia*, an implantable power module 80 having a hermetically sealed casing made of metal such as titanium (column 8, line 64), a power supply 60, a power control management circuit 70. see column 9, lines 9-13. It further discloses a couple for remotely communicate with the power supply through induction and electrically connected to the circuit 70. See column 9, lines 46-54. And a connector 50 for connecting to an implantable medical device 10. See column 9, line 2. The power control providing various patterns of charge to ensure the promotion of the medical device. See column 9, lines 25-45.

Claim Rejections - 35 USC § 103

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

Claims 2, 7-9, 11, 18, 19 and 36-45 are rejected under 35 U.S.C. 103(a) as being unpatentable over MICHELSON (US 6,120,502) in view of ECHARRI et al. (US 6,278,258).

Reference '502 fails to disclose the specific features of its power controller.

Reference '258 specifically teaches an implantable power management system located inside the implantable device having, *inter alia*, processor for supervising the charging and discharging operation of the power module being rechargeable battery or capacitors (column 1, line 49). See column 5, lines 5-40. It senses and responds to temperature changes, charging capacity, overcharge ect. to the power module. The communication may be done by rf means. It would have been obvious to one having ordinary skill in the art to have employed the features of

Art Unit: 2838

the power management controller of '258 to the controller of '502 in order to not only control and monitor the discharge of the power module but actually control the charging of the power module to provide a safer and more reliable implantable device.

Furthermore both references don't disclose the various communication means including light, coil ect. It would have been obvious to one having ordinary skill in the art at the time the invention was made to have employed any appropriate communication means, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. *In re Leshin*, 125 USPQ 416.

Claims 3 and 46-65 rejected under 35 U.S.C. 103(a) as being unpatentable over MICHELSON (US 6,120,502) in view of GARGANO et al. (US 5,629,678). Reference '502 fails to disclose a homing device imbedded on the implantable device in order to track it. Reference '678 teaches an apparatus for tracking using an implantable receiver. It uses radio frequency to track and recover the device. It would have been obvious to one having ordinary skill in the art to have placed a homing device in the medical device for the purpose of relocating and facilitate the rapid recovery of the device.

Furthermore, both references do not disclose the many different homing devices including those that uses light, radioactive isotope ect. It would have been obvious to one having ordinary skill in the art at the time the invention was made to have selected the appropriate homing signal for the implantable device and/or affecting patient, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its

Art Unit: 2838

suitability for the intended use as a matter of obvious design choice. *In re Leshin*, 125 USPQ 416. Moreover, it would have been obvious to one having ordinary skill in the art at the time the invention was made to have selected any appropriate range of light since it has been held that where the general conditions of a claim are disclosed in the prior art, discovering the optimum or workable ranges involves only routine skill in the art. *In re Aller*, 105 USPQ 233.

Claims 4, 6 and 12-16 are rejected under 35 U.S.C. 103(a) as being unpatentable over MICHELSON (US 6,120,502). Reference does not disclose the power module being a primary battery and or the battery/power controller is partially surrounded by ferrite coil for inductive coupling. It would have been obvious to one having ordinary skill in the art at the time the invention was made to have selected the power module to include nonrechargeable batteries and surround the battery and/or power controller with ferrite coil to induce inductive charging, since it has been held to be within the general skill of a worker in the art to select a known material on the basis of its suitability for the intended use as a matter of obvious design choice. *In re Leshin*, 125 USPQ 416.

Allowable Subject Matter

Claims 20-30, 34, 35, 66, 69 and 70 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. The references made of record fails to disclose or suggest an energy drain circuit for rapid depletion of the energy in the power module (claims 20-25), a heat absorption material in thermal contact with the storage device (claims 26-

Art Unit: 2838


30), the medical device/implantable module is remotely located from the power module through an external hermetically sealed plug (claims 34, 35, 69 and 70) and an extra connector for an additional device (claim 66).

Conclusion


Any inquiry concerning this communication should be directed to the Examiner at the below-listed number.

Any inquiry of a general nature or relating to the status of this application should be directed to the receptionist whose telephone number is 703 308 0956, Monday-Friday, 830am to 5:00pm, EST.

By:



EDWARD TSO
Primary Examiner
703 308 2823



Substitute for form 1449/APTO		Complete if Known			
		Application Number	10/310,390		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Filing Date	December 5, 2002		
		First Named Inventor	Hisashi Tsukamoto et al.		
		Art Unit	2838		
		Examiner Name	Edward H. Tso		
Sheet	1	of	1	Attorney Docket number	Q147-US1

Examiner Initials*	Cite No.	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number - Kind Code* (if known)		
[Handwritten Initials]		US-3,942,535	03-09-1976	Schulman
		US-4,010,760	03-08-1977	Kraska et al.
		US-4,119,103	10-10-1978	Jirak
		US-4,197,850	04-15-1980	Schulman et al.
		US-4,469,104	09-04-1984	Peers-Trevarton
		US-B1 4,232,679	05-31-1988	Schulman
		US-5,314,451	05-24-1994	Muller
		US-5,411,538	05-02-1995	Lin
		US-5,573,551	11-12-1996	Lin
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		
		US-		

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Office ²	Number ³	Kind ⁴ (if known)		
		</				

Examiner Signature		Date Considered	01.04
--------------------	--	-----------------	-------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form which next communication to applicant.
¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible.

BEST AVAILABLE COPY

Notice of References Cited

Application/Control No.

10/310,390

Applicant(s)/Patent Under

Reexamination

TSUKAMOTO ET AL.

Examiner

Edward H Tso

Art Unit

2838

Page 1 of 1

U.S. PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Name	Classification
	A	US-5,629,678	05-1997	Gargano et al.	340/573.4
	B	US-6,120,502	09-2000	Michelson, Gary Karlin	606/61
	C	US-6,278,258	08-2001	Echarri et al.	320/130
	D	US-6,426,628	07-2002	Palm et al.	324/427
	E	US-			
	F	US-			
	G	US-			
	H	US-			
	I	US-			
	J	US-			
	K	US-			
	L	US-			
	M	US-			

FOREIGN PATENT DOCUMENTS

*		Document Number Country Code-Number-Kind Code	Date MM-YYYY	Country	Name	Classification
	N					
	O					
	P					
	Q					
	R					
	S					
	T					

NON-PATENT DOCUMENTS

*		Include as applicable: Author, Title Date, Publisher, Edition or Volume, Pertinent Pages)
	U	
	V	
	W	
	X	

*A copy of this reference is not being furnished with this Office action. (See MPEP § 707.05(a).)
Dates in MM-YYYY format are publication dates. Classifications may be US or foreign.

JUN 04 2004

From the
INTERNATIONAL PRELIMINARY EXAMINING AUTHORITY

To:
MARY ELIZABETH BUSH
QUALLION LLC LEGAL DEPARTMENT
12744 SAN FRANANDO RD.
P.O. BOX 923127
SYLMAR, CA 91392-3127

PCT

**NOTIFICATION OF TRANSMITTAL OF
INTERNATIONAL PRELIMINARY
EXAMINATION REPORT**

(PCT Rule 71.1)

Date of Mailing
(day/month/year)

01 JUN 2004

Applicant's or agent's file reference

Q147-PC1

IMPORTANT NOTIFICATION

International application No.

PCT/US03/24168

International filing date (day/month/year)

31 July 2003 (31.07.2003)

Priority date (day/month/year)

09 August 2002 (09.08.2002)

Applicant

QUALLION LLC

1. The applicant is hereby notified that this International Preliminary Examining Authority transmits herewith the international preliminary examination report and its annexes, if any, established on the international application.
2. A copy of the report and its annexes, if any, is being transmitted to the International Bureau for communication to all the elected Offices.
3. Where required by any of the elected Offices, the International Bureau will prepare an English translation of the report (but not of any annexes) and will transmit such translation to those Offices.
4. **REMINDER**

The applicant must enter the national phase before each elected Office by performing certain acts (filing translations and paying national fees) within 30 months from the priority date (or later in some Offices)(Article 39(1))(see also the reminder sent by the International Bureau with Form PCT/IB/301).

Where a translation of the international application must be furnished to an elected Office, that translation must contain a translation of any annexes to the international preliminary examination report. It is the applicant's responsibility to prepare and furnish such translation directly to each elected Office concerned.

For further details on the applicable time limits and requirements of the elected Offices, see Volume II of the PCT Applicant's Guide.

Name and mailing address of the IPEA/US

Mail Stop PCT, Attn: IPEA/US
Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Facsimile No. (703) 305-3230

Form PCT/IPEA/416 (July 1992)

Authorized officer

Michael Sherry

Telephone No. 571 272 2800

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference Q147-PC1		FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/US03/24168	International filing date (day/month/year) 31 July 2003 (31.07.2003)	Priority date (day/month/year) 09 August 2002 (09.08.2002)	
International Patent Classification (IPC) or national classification and IPC IPC(7): H01M 10/46 and US Cl.: 320/112			
Applicant QUALLION LLC			
<p>1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</p> <p>2. This REPORT consists of a total of <u>3</u> sheets, including this cover sheet.</p> <p><input type="checkbox"/> This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).</p> <p>These annexes consist of a total of <u>0</u> sheets.</p>			
<p>3. This report contains indications relating to the following items:</p> <p>I <input checked="" type="checkbox"/> Basis of the report</p> <p>II <input type="checkbox"/> Priority</p> <p>III <input type="checkbox"/> Non-establishment of report with regard to novelty, inventive step and industrial applicability</p> <p>IV <input type="checkbox"/> Lack of unity of invention</p> <p>V <input checked="" type="checkbox"/> Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement</p> <p>VI <input type="checkbox"/> Certain documents cited</p> <p>VII <input type="checkbox"/> Certain defects in the international application</p> <p>VIII <input type="checkbox"/> Certain observations on the international application</p>			
Date of submission of the demand 09 March 2004 (09.03.2004)		Date of completion of this report 13 April 2004 (13.04.2004)	
Name and mailing address of the IPEA/US Mail Stop PCT, Attn: IPEA/US Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450 Facsimile No. (703) 305-3230		Authorized officer <i>Norman Chapman</i> Michael Sherry Telephone No. 571 272 2800	

Form PCT/IPEA/409 (cover sheet)(July 1998)

I. Basis of the report**1. With regard to the elements of the international application:***

- ☒ the international application as originally filed.
- ☒ the description:
pages 1-12 _____ as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.
- ☒ the claims:
pages 13-20 _____, as originally filed
pages NONE _____, as amended (together with any statement) under Article 19
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.
- ☒ the drawings:
pages 1-10 _____, as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.
- ☐ the sequence listing part of the description:
pages NONE _____, as originally filed
pages NONE _____, filed with the demand
pages NONE _____, filed with the letter of _____.

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language _____ which is:

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in printed form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages NONE
- ☐ the claims, Nos. NONE
- ☐ the drawings, sheets/fig NONE

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.

V. Reasoned statement under Rule 66.2(a)(ii) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. STATEMENT**

Novelty (N)	Claims <u>1-70</u>	YES
	Claims <u>NONE</u>	NO
Inventive Step (IS)	Claims <u>1-70</u>	YES
	Claims <u>NONE</u>	NO
Industrial Applicability (IA)	Claims <u>1-70</u>	YES
	Claims <u>NONE</u>	NO

2. CITATIONS AND EXPLANATIONS

Claims 1-70 meet the criteria set out in PCT Article 33(2)-(3), because the prior art does not teach or fairly suggest an implantable power module comprising, inter alia, a hermetically sealed biocompatible case; an electrochemical energy storage device housed within said case; a power management circuit housed within said case; a couple for remotely communicating with said power module; said couple electrically connected to said power management circuit; and at least one connector for functionally interconnecting said electrochemical energy storage device to an implantable medical device.

Claims 1-70 meet the criteria set out in PCT Article 33(4), and thus meet industrial applicability because the subject matter claimed can be made or used in industry.



EXPRESS MAIL

UNITED STATES POSTAL SERVICE[®]

www.uspb



Addressee Copy
Label 11-F June 2002



**EXPRESS
MAIL**

UNITED STATES POSTAL SERVICE®

Post Office ~~to~~ Addressee

ORIGIN (POSTAL USE ONLY)				DELIVERY (POSTAL USE ONLY)			
PO ZIP Code 07406	Day of Delivery <input type="checkbox"/> Next <input checked="" type="checkbox"/> Second		Flat Rate Envelope <input type="checkbox"/>	Mo.	Day	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Date In 7/24/01	Mo.	Day	Postage \$ 1.95	Delivery Attempt	Time		Employee Signature
Time In 12:00 PM	<input checked="" type="checkbox"/> 12 Noon <input type="checkbox"/> 3 PM	Military	Return Receipt Fee	Mo.	Day	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
<input type="checkbox"/> AM <input checked="" type="checkbox"/> PM	<input type="checkbox"/> 2nd Day <input type="checkbox"/> 3rd Day	Int'l Alpha Country Code	COD Fee	Delivery Date	Time		Employee Signature
Weight			Insurance Fee	Mo.	Day	Time <input type="checkbox"/> AM <input type="checkbox"/> PM	Employee Signature
Box # 023	Acceptance Clerk Initials		Total Postage & Fees \$	<input type="checkbox"/> WARRANT OR SIGNATURE (Domestic Only) Additional merchandise insurance is void if washer of signature delivery is to be made without obtaining signature of addressee or addressee's agent (if delivery is to be made to a location other than the location) and I authorize that delivery employee's signature constitute receipt of delivery.			
No Delivery	<input type="checkbox"/> Weekend <input type="checkbox"/> Holiday			NO DELIVERY <input type="checkbox"/> Washed <input type="checkbox"/> Holiday Customer Signature _____			

FROM: (PLEASE PRINT) WALLION LLC 60 BOX 12512 SYLMAR	TO: (PLEASE PRINT) CUMULATIVE PD BOX 1430 ALEXANDRIA
PHONE: 810-434-4000	JUL 29 2004 EXPRESS MAIL LABEL DATE (M)
Express Mail Corporate Acct. No. 82250274	Express Mail Corporate Acct. No. 82250274

PRESS HARD.
You are making 3 copies.

FOR PICKUP OR TRACKING CALL 1-800-222-1811 www.usps.com

pay only

